B
Bernard Charpentier
Researcher at University of Paris-Sud
Publications - 165
Citations - 7937
Bernard Charpentier is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 44, co-authored 165 publications receiving 7634 citations. Previous affiliations of Bernard Charpentier include Necker-Enfants Malades Hospital.
Papers
More filters
Journal ArticleDOI
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Carl G. Groth,Lars Bäckman,José-Maria Morales,Roy Y. Calne,Henri Kreis,Philippe Lang,Jean-Louis Touraine,Kerstin Claesson,Josep M. Campistol,Dominique Durand,L. Wramner,Christina Brattström,Bernard Charpentier +12 more
TL;DR: Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus as discussed by the authors.
Journal ArticleDOI
Costimulation blockade with belatacept in renal transplantation.
Flavio Vincenti,Christian P. Larsen,Antoine Durrbach,Thomas Wekerle,Björn Nashan,Gilles Blancho,Philippe Lang,Josep M. Grinyó,Philip F. Halloran,Kim Solez,David Hagerty,Elliott Levy,Wenjiong Zhou,Kannan Natarajan,Bernard Charpentier +14 more
TL;DR: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation and may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Journal ArticleDOI
Effect of Plasma Protein Adsorption on Protein Excretion in Kidney-Transplant Recipients with Recurrent Nephrotic Syndrome
Jacques Dantal,Edith Bigot,Willy M. J. M. Bogers,Angelo Testa,Faical Kriaa,Yannick Jacques,Bruno Hurault de Ligny,Patrick Niaudet,Bernard Charpentier,Jean P. Soulillou +9 more
TL;DR: Adsorption of plasma protein decreases urinary protein excretion in patients with recurrence of the nephrotic syndrome after renal transplantation, and studies of the adsorbed proteins should provide information about the mechanism of this disease.
Journal ArticleDOI
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Flavio Vincenti,Christian P. Larsen,Josefina Alberú,Barbara A. Bresnahan,Valter Duro Garcia,J. Kothari,Peter Lang,E. Mancilla Urrea,Pablo U. Massari,G. A. Mondragón‐Ramirez,Rafael Reyes-Acevedo,Kim Rice,Lionel Rostaing,Steven M. Steinberg,J Xing,M. Agarwal,M. B. Harler,Bernard Charpentier +17 more
TL;DR: Belatacept‐treated patients maintained a high rate of patient and graft survival that was comparable to cyclosporine‐ treated patients, despite an early increased occurrence of acute rejection and PTLD.
Sirolimus (rapamycin)-based therapy in human renal transplantation
Carl G. Groth,Maria Morales,Roy Y. Calne,Henri Kreis,Philippe Lang,Kerstin Claesson,Josep M. Campistol,L. Wramner,Bernard Charpentier +8 more
TL;DR: Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.